Products
Our mission is to bring life-changing therapeutics to people living with rare diseases.
© 2024 Zevra Therapeutics. All rights reserved. | Privacy Policy | Terms of Use
Product Name
Indication
Commercial Partner
Milestone
Urea Cycle Disorders Commercial Product
Olpruva®
sodium phenylbutyrate for oral suspension
Certain Urea Cycle Disorders
Zevra acquires Acer Therapeutics in 2023
View Press Release
OLPRUVA (sodium phenylbutyrate) for oral suspension approved in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
For more information visit www.olpruva.com.
ADHD Commercial Product
AZSTARYS®
serdexmethylphenidate and dexmethylphenidate
Attention Deficit Hyperactivity Disorder (ADHD) in patients age six and older
Corium Inc.
Potential to reach one or more milestones during 2024 and continued royalty revenue.
Approved by the FDA in 2021, AZSTARYS is a prodrug for the treatment of ADHD in patients age six years or older.
For more information visit www.azstarys.com.
AZSTARYS® is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep AZSTARYS® in a safe place to prevent misuse and abuse. Selling or giving away AZSTARYS® may harm others and is against the law.
OLPRUVA is a registered trademark of Acer Therapeutics Inc., a wholly owned subsidiary of Zevra Therapeutics, Inc.